ArticleJournal of thoracic disease2026
ZKSCAN3 mitigates lipopolysaccharide-induced acute lung injury by restraining excessive autophagy via activation of the mTOR pathway.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lung injury (ALI) is a critical condition marked by dysregulated inflammation and autophagic imbalance. Zinc-finger with KRAB and SCAN domains 3 (ZKSCAN3) is a master transcriptional repressor of autophagy, yet its role in ALI pathogenesis remains unclear. The aim of this study is to elucidate the functional role and underlying mechanisms of ZKSCAN3 in ALI. Methods: ALI was induced in C57BL/6 mice and A549 alveolar epithelial cells by lipopolysaccharide (LPS). ZKSCAN3 was overexpressed using plasmid transfection to evaluate its therapeutic potential. Lung injury was assessed by histopathology, wet-to-dry ratio (W/D ratio), and inflammatory cytokine levels [tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6]. Autophagic activity was evaluated via transmission electron microscopy(TEM), immunofluorescence, and western blotting for LC3-II, Beclin-1, and P62. The involvement of the mTOR pathway was investigated by examining the phosphorylation status of mTOR. Results: ZKSCAN3 expression was significantly downregulated in both LPS-induced lung tissues and A549 cells. Overexpression of ZKSCAN3 markedly alleviated LPS-induced pulmonary edema, alveolar damage, and the surge of pro-inflammatory cytokines. Mechanistically, ZKSCAN3 overexpression suppressed excessive autophagic flux, as evidenced by a decreased LC3-II/LC3-I ratio and Beclin-1 expression, and increased accumulation of P62. Furthermore, this protective effect was associated with a notable increase in mTOR phosphorylation, indicating reactivation of the mTOR-autophagy inhibitory axis. Conclusions: Our findings reveal that downregulation of ZKSCAN3 contributes to the pathogenesis of LPS-induced ALI. Restoration of ZKSCAN3 exerts a protective effect by reining in excessive autophagy, through activation of the mTOR signaling pathway. This positions the ZKSCAN3-mTOR axis as a potential therapeutic target for ALI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.